- Home
- RWT vs GYRE Comparison
RWT vs GYRE Comparison
Compare RWT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RWT
- GYRE
- Stock Information
- Founded
- RWT 1994
- GYRE 2002
- Country
- RWT United States
- GYRE United States
- Employees
- RWT N/A
- GYRE N/A
- Industry
- RWT Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- RWT Real Estate
- GYRE Health Care
- Exchange
- RWT Nasdaq
- GYRE Nasdaq
- Market Cap
- RWT 756.1M
- GYRE 897.1M
- IPO Year
- RWT 1995
- GYRE N/A
- Fundamental
- Price
- RWT $6.12
- GYRE $8.13
- Analyst Decision
- RWT Buy
- GYRE
- Analyst Count
- RWT 11
- GYRE 0
- Target Price
- RWT $7.59
- GYRE N/A
- AVG Volume (30 Days)
- RWT 1.1M
- GYRE 219.2K
- Earning Date
- RWT 07-31-2025
- GYRE 08-12-2025
- Dividend Yield
- RWT 11.76%
- GYRE N/A
- EPS Growth
- RWT 105.35
- GYRE N/A
- EPS
- RWT 0.21
- GYRE 0.02
- Revenue
- RWT $241,796,000.00
- GYRE $100,643,000.00
- Revenue This Year
- RWT N/A
- GYRE $21.04
- Revenue Next Year
- RWT $3.43
- GYRE $89.64
- P/E Ratio
- RWT $29.02
- GYRE $101.65
- Revenue Growth
- RWT 29.65
- GYRE N/A
- 52 Week Low
- RWT $4.68
- GYRE $6.11
- 52 Week High
- RWT $8.15
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- RWT 67.17
- GYRE 48.99
- Support Level
- RWT $5.40
- GYRE $6.98
- Resistance Level
- RWT $5.72
- GYRE $7.80
- Average True Range (ATR)
- RWT 0.15
- GYRE 0.49
- MACD
- RWT 0.06
- GYRE 0.05
- Stochastic Oscillator
- RWT 92.31
- GYRE 73.25
About RWT Redwood Trust Inc.
Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.